These authors contributed equally to this work.

## **References**


[14] Gregoriadis G, Davis D, Davies A. Liposomes as immunological adjuvants: Antigen incorporation studies. Vaccine. 1987;**5**(2):145-151

**References**

312 Liposomes

**31**(11):583-594

2012;**12**(11):786-798

2003;**101**(2):594-601

2013;**8**(1):102

Drug Delivery. 2011;**2011**:591325

Nanomedicine. 2015;**10**:975-999

Vaccine. 2001;**19**(25-26):3509-3517

Drug Delivery Reviews. 1998;**32**(3):273-287

[1] Good MF, Hawkes MT, Yanow SK. Humanized mouse models to study cell-mediated immune responses to liver-stage malaria vaccines. Trends in Parasitology. 2015;

[2] Tyagi RK, Miles B, Parmar R, Garg NK, Dalai SK, Baban B, et al. Human IDO-competent, long-lived immunoregulatory dendritic cells induced by intracellular pathogen, and

[3] Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: Progress, promise and challenges. Nature Reviews Immunology.

[4] Arnold L, Tyagi RK, Meija P, Swetman C, Gleeson J, Perignon JL, et al. Further improvements of the *P*. *falciparum* humanized mouse model. PLoS One. 2011;**6**(3):e18045

[5] Arnold L, Tyagi RK, Mejia P, Van Rooijen N, Perignon JL, Druilhe P. Analysis of innate defences against *Plasmodium falciparum* in immunodeficient mice. Malaria Journal. 2010;**9**:197

[6] Hu Z, Van Rooijen N, Yang YG. Macrophages prevent human red blood cell reconstitu-

[7] Jordan MB, van Rooijen N, Izui S, Kappler J, Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood.

[8] Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. Journal of

[9] Bozzuto G, Molinari A. Liposomes as nanomedical devices. International Journal of

[10] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: Classification, preparation, and applications. Nanoscale Research Letters.

[11] Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, *Listeria monocytogenes*.

[12] Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional

[13] Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, Feketeova E, et al. Targeting immune response induction with cochleate and liposome-based vaccines. Advanced

liposomes and alum. Infection and Immunity. 2000;**68**(1):54-63

their fate in humanized mice. Scientific Reports. 2017;**7**:41083

tion in immunodeficient mice. Blood. 2011;**118**(22):5938-5946


[43] Mishra D, Dubey V, Asthana A, Saraf DK, Jain NK. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine. 2006;**24**(22):4847-4855

[30] Janga KY, Jukanti R, Velpula A, Sunkavalli S, Bandari S, Kandadi P, et al. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur

[31] Lowell GH, Smith LF, Seid RC, Zollinger WD. Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. The Journal of

[32] Szoka F, Jr., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America. 1978;**75**(9):4194-4198

[33] Cortesi R, Esposito E, Gambarin S, Telloli P, Menegatti E, Nastruzzi C. Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. Journal of

[34] Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in

[35] Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochimica et

[36] Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Letters. 1990;**268**(1):235-237

[37] Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times.

[38] Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. Biochimica et Biophysica Acta.

[39] Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochimica et Biophysica Acta.

[40] Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in

[41] Kono K. Thermosensitive polymer-modified liposomes. Advanced Drug Delivery

[42] Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Advanced Drug Delivery

Pharmazeutische Verfahrenstechnik eV. 2012;**80**(2):347-357

Experimental Medicine. 1988;**167**(2):658-663

314 Liposomes

Microencapsulationcapsulation. 1999;**16**(2):251-256

vivo. Biochimica et Biophysica Acta. 1991;**1066**(1):29-36

Biochimica et Biophysica Acta. 1991;**1070**(1):187-192

Biophysica Acta. 1990;**1029**(1):91-97

1991;**1062**(1):77-82

1992;**1113**(2):171-199

Lipid Research. 2003;**42**(6):463-478

Reviews. 2001;**53**(3):307-319

Reviews. 2001;**53**(3):285-305


[56] Tiwari S, Goyal AK, Khatri K, Mishra N, Vyas SP. Gel core liposomes: An advanced carrier for improved vaccine delivery. Journal of Microencapsulation. 2009;**26**(1):75-82

[57] Tiwari S, Goyal AK, Mishra N, Khatri K, Vaidya B, Mehta A, et al. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine. Journal of Controlled Release: Official Journal of the Controlled Release Society.

[58] Tyagi RK, Garg NK, Dalai SK, Awasthi A. Transdermal immunization of *P*. *falciparum* surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity. Human

[59] Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, et al. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar eryth-

[60] Green AE, Rose PG. Pegylated liposomal doxorubicin in ovarian cancer. International

[61] Kubicka-Wolkowska J, Kedzierska M, Lisik-Habib M, Potemski P. Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report

and review of the literature. Oncology Letters. 2016;**12**(6):5332-5334

rodysesthesia syndrome. European Journal of Dermatology. 2008;**18**(5):566-570

Vaccines & Immunotherapeutics. 2016;**12**(4):990-992

Journal of Nanomedicine. 2006;**1**(3):229-239

2009;**140**(2):157-165

316 Liposomes

## *Edited by Angel Catala*

Liposomes have received increased attention in recent years. Nevertheless, liposomes, due to their various forms and applications, require further investigation. These structures can deliver both hydrophilic and hydrophobic drugs. Preparation of liposomes results in different properties for these systems. In addition, there are many factors and difficulties that affect the development of liposome drug delivery structure. The purpose of this book is to concentrate on recent developments on liposomes. The articles collected in this book are contributions by invited researchers with a longstanding experience in different research areas. We hope that the material presented here is understandable to a broad audience, not only scientists but also people with general background in many different biological sciences. This volume offers you upto-date, expert reviews of the fast-moving field of liposomes.

Photo by Jezperklauzen / iStock

Liposomes

Liposomes

*Edited by Angel Catala*